Press Kit

I believe that the new therapies we are acquiring with Marker in this transaction represent the next major leap forward in cell therapy for cancer. The merger adds to our product pipeline a synergistic portfolio of highly-differentiated T cell therapies that has demonstrated potentially groundbreaking results in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.

Peter L. Hoang

President & CEO

With this merger, I believe we have the opportunity to significantly disrupt the CAR-T and TCR field. Compared to current gene-modified T cell therapies such as CAR-T and TCR, the therapies we are acquiring in this transaction are highly efficacious and extremely durable, without the need for lymphodepletion before infusion, non gene-modified, significantly less toxic than CAR-T, multi-antigen specific, capable of driving an endogenous immune response, and capable of addressing patients currently inaccessible to CAR-T therapies.

Peter L. Hoang

President & CEO